Clinical and pharmacological group: & nbsp

Glucocorticosteroids

Included in the formulation
АТХ:

D.07.A.B   Corticosteroids are moderately active (group II)

D.07.A.B.03   Flumethasone

Pharmacodynamics:

Glucocorticosteroids for external use. Has a pronounced anti-inflammatory, antiallergic, antiexudative and antipruritic effect.

Interaction with intracellular glucocorticoid receptors - the formation of dimers of the glucocorticoid-glucocorticoid receptor complex. The steroid hormone complex with the receptor is transported to the nucleus of the cell. In the nucleus this complex interacts with effector elements localized on the acceptor sites of the chromatin (genes). As a result of the interaction, stimulation or inhibition of gene expression occurs; this leads to a change in the synthesis of matrix RNA and proteins.

The anti-inflammatory effect of flumethasone is due to several factors.

1. The drug induces the synthesis of lipocortin, which inhibits the activity of phospholipase A2. Inhibition of phospholipase-mediated A2 hydrolysis of membrane phospholipids of damaged tissues prevents the formation of arachidonic acid. The disruption of the formation of arachidonic acid actually means inhibition of the synthesis of prostaglandins, since arachidonic acid is a substrate for further metabolism along the cyclooxygenase pathway,and also on the lipoxygenase pathway with the corresponding inhibition of leukotriene synthesis.

2. The anti-inflammatory effect of glucocorticoids is potentiated by their ability to inhibit the expression of COX-2 genes, which also leads to a decrease in the synthesis of prostaglandins in the inflammatory focus, including pro-inflammatory prostaglandins E2 and I2.

3. Flumethasone inhibits the expression of molecules of intercellular adhesion in the endothelium of blood vessels, violating the penetration of neutrophils and monocytes into the focus of inflammation.

With external application prevents the accumulation of neutrophils, which leads to a decrease in inflammatory exudate and production of lymphokines, inhibition of migration of macrophages, a reduction in infiltration and granulation.

Reduces the appearance or eliminates inflammatory skin reaction, softens burning and pain.

Pharmacokinetics:Absorption from the skin surface is insignificant; association with plasma proteins; biotransformation of the liver (after entering the systemic circulation) to inactive metabolites (CYP3A4); excretion mainly by the kidneys in the form of inactive metabolites.
Indications:Various forms of subacute and acute eczema, hives, itchy allergic etiology, generalized and limited prurigo,diaper rash, erythema multiforme, lichen planus, seborrhea, psoriasis of the scalp. Acute dermatitis after insolation, irradiation with a quartz lamp, X-rays, burns of I-II degree; insect bites.

XII.L20-L30.L20.8   Other atopic dermatitis

XII.L20-L30.L21   Seborrheic dermatitis

XII.L20-L30.L23   Allergic contact dermatitis

XII.L20-L30.L24   Simple irritant contact dermatitis

XII.L20-L30.L28.0   Simple chronic lichen

XII.L20-L30.L29   Itching

XII.L20-L30.L30.0   Coin-like eczema

XII.L40-L45.L40   Psoriasis

XII.L50-L54.L50   Hives

XII.L50-L54.L51   Erythema multiforme

XII.L55-L59.L55   Sunburn

XII.L55-L59.L56.2   Photocontact dermatitis [berloque dermatitis]

XII.L55-L59.L58   Radiation dermatitis radiation

Contraindications:Bacterial, viral, fungal skin diseases, skin tuberculosis, skin manifestations of syphilis, skin tumors, precancerous skin diseases, trophic ulcers of the shins associated with varicose veins, skin reactions after vaccination, conjunctival lesions, hypersensitivity to flumethasone; infants and young children; I trimester of pregnancy.
Carefully:

Extensive lesions of the skin and mucous membranes.

In children, efficacy and safety have not been studied.

Pregnancy and lactation:

Recommendations for FDA - Category C. Qualitative and well-controlled studies on humans have not been conducted. Animal studies have shown that glucocorticoids for topical application can be absorbed into the systemic circulation and have side effects on the fetus. Do not apply!

There is no information on the penetration into breast milk. Do not apply!

Dosing and Administration:Apply a thin, uniform layer in the form of 0.02% ointment, cream or lotion 1 to 3 times a day. To prevent recurrence of the disease apply for 1 week 1 time per day. The course of treatment is 1-2 weeks.
Side effects:

Burning, itching, steroid acne, striae, dry skin, folliculitis.

With long-term use - skin atrophy and skin stretching, local hirsutism, hypertrichosis, telangiectasia, purpura, skin pigmentation disorders (hypopigmentation), alopecia, especially in women.

With long-term use and / or application to large surfaces, systemic side effects, characteristic of glucocorticosteroids, are possible.

Overdose:

Symtomas: itching and burning of the skin at the site of application, hyperglycemia, glucosuria, Itenko-Cushing syndrome.

Treatment: symptomatic on the background of a gradual withdrawal of the drug.

Interaction:No data
Special instructions:

The use of flumethasone on large surfaces is possible only under the condition of short-term treatment.

With great care apply in pregnancy and in children - as an exception and on small surfaces of the skin.

In the case of flumethasone for common or pink acne, the disease may worsen.

Avoid contact with flumethasone on conjunctivitis.

With prolonged use or application on large surfaces: cataract, diabetes, glaucoma, tuberculosis.

Instructions
Up